Purpose: To evaluate the efficacy and safety of atropine 0.01% in slowing myopia progression in European paediatric patients. Methods: Retrospective, medical records review study. Medical charts of paediatric patients with a myopia progression > 0.5 D/year treated with atropine 0.01% for at least 1 year were included. Patients receive a complete ophthalmic examination before and 12 months after initiation of atropine treatment. A group of myopic untreated children serves as a control group. The rate of myopia progression at baseline and 12 months after treatment with atropine was evaluated. The rate of myopia progression in treated and untreated patients was also compared. Adverse events were recorded. Results: Medical records of 52 treated and 50 control subjects were analysed. In the atropine group, the mean rate of myopia progression after 12 months of treatment (−0.54 ± 0.61 D) was significantly slower compared with the baseline progression (−1.20 ± 0.64 D; p < 0.0001) and to the progression in the control group (−1.09 ± 0.64; p < 0.0001). The responders patients were 41/52 (79%), whereas 11/52 patients (21%) showed a progression > 0.50 D despite treatment. The only adverse event was temporary photophobia in five patients (9.6%), severe adverse events were not reported, and none of the patients discontinued the treatment. Conclusion: Low-dose atropine significantly slowed the rate of myopia progression in European paediatric patients with a favourable safety profile.

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients / M. Sacchi, M. Serafino, E. Villani, E. Tagliabue, S. Luccarelli, F. Bonsignore, P. Nucci. - In: ACTA OPHTHALMOLOGICA. - ISSN 1755-375X. - 97:8(2019 Dec 01), pp. e1136-e1140. [Epub ahead of print] [10.1111/aos.14166]

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients

E. Villani;S. Luccarelli;F. Bonsignore
Penultimo
;
P. Nucci
Ultimo
2019-12-01

Abstract

Purpose: To evaluate the efficacy and safety of atropine 0.01% in slowing myopia progression in European paediatric patients. Methods: Retrospective, medical records review study. Medical charts of paediatric patients with a myopia progression > 0.5 D/year treated with atropine 0.01% for at least 1 year were included. Patients receive a complete ophthalmic examination before and 12 months after initiation of atropine treatment. A group of myopic untreated children serves as a control group. The rate of myopia progression at baseline and 12 months after treatment with atropine was evaluated. The rate of myopia progression in treated and untreated patients was also compared. Adverse events were recorded. Results: Medical records of 52 treated and 50 control subjects were analysed. In the atropine group, the mean rate of myopia progression after 12 months of treatment (−0.54 ± 0.61 D) was significantly slower compared with the baseline progression (−1.20 ± 0.64 D; p < 0.0001) and to the progression in the control group (−1.09 ± 0.64; p < 0.0001). The responders patients were 41/52 (79%), whereas 11/52 patients (21%) showed a progression > 0.50 D despite treatment. The only adverse event was temporary photophobia in five patients (9.6%), severe adverse events were not reported, and none of the patients discontinued the treatment. Conclusion: Low-dose atropine significantly slowed the rate of myopia progression in European paediatric patients with a favourable safety profile.
atropine; children; European; progressive myopia
Settore MED/30 - Malattie Apparato Visivo
Article (author)
File in questo prodotto:
File Dimensione Formato  
Manuscript atropine.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 121.13 kB
Formato Adobe PDF
121.13 kB Adobe PDF Visualizza/Apri
aos.14166.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 158.57 kB
Formato Adobe PDF
158.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/664216
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 34
social impact